Inhibitory role for GABA in atherosclerosis.
Ying Yang1, Hui Luo, Long-Xian Cheng
1Department of Cardiology, Union Hospital, Huazhong University of Science and Technology, Wuhan 430022, China.
Medical Hypotheses
|October 1, 2013
Summary
γ-Aminobutyric acid (GABA) inhibits immune cells involved in atherosclerosis pathogenesis. This suggests GABA could be a potential therapy for atherosclerosis by targeting immune cells.
Area of Science:
- Immunology
- Neuroscience
- Cardiovascular Disease
Background:
- γ-Aminobutyric acid (GABA) is a primary inhibitory neurotransmitter in the central nervous system.
- GABA also exhibits inhibitory functions within the immune system, modulating immune cell activities.
- Atherosclerosis is a chronic inflammatory condition driven by immune responses in artery walls.
Purpose of the Study:
- To investigate the potential of GABA as a therapeutic agent for atherosclerosis.
- To explore GABA's immunomodulatory effects in the context of atherosclerosis pathology.
Main Methods:
- Review of GABA's known effects on immune cell functions relevant to atherosclerosis.
- Analysis of GABA's role in neuroprotection and its relevance to atherosclerosis complications.
Main Results:
- GABA influences key immune processes implicated in atherosclerosis, including monocyte migration, macrophage cholesterol efflux, regulatory T cell proliferation, and inflammatory cytokine secretion.
- GABA demonstrates neuroprotective effects against ischemic injury, a complication associated with atherosclerosis.
Conclusions:
- GABA's multifaceted inhibitory effects on immune cells suggest a significant role in modulating atherosclerosis.
- GABA represents a promising candidate for immune cell-targeted therapy in atherosclerosis and its associated neurological complications.
Related Concept Videos
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:21G-Protein Gated Ion Channels
GPCRs are primarily responsible for our sense of smell, taste, and vision. The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory organs,...
Sensory organs,...
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...